Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

Huda Mussaffi; Naama Fisch Shvalb; Haim Ben-Zvi; Gilat Livni; Meir Mei-Zahav; Dario Prais; Patrick Stafler; Guy Steuer; Hannah Blau

doi:10.1097/INF.0000000000000972

Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

Huda Mussaffi
, Naama Fisch Shvalb
, Haim Ben-Zvi
, Gilat Livni
, Meir Mei-Zahav
, Dario Prais
, Patrick Stafler
, Guy Steuer
, Hannah Blau^*

^*Corresponding author for this work

Schneider Childrens Medical Center Israel
Clalit Health Services
Tel Aviv University
Rabin Medical Center Israel

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second% predicted remained unchanged during 12 months.

Original language	English
Pages (from-to)	216-219
Number of pages	4
Journal	Pediatric Infectious Disease Journal
Volume	35
Issue number	2
DOIs	https://doi.org/10.1097/INF.0000000000000972
State	Published - 1 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

airway infection
cystic fibrosis
extended spectrum β-lactamase
producing Enterobacteriaceae

Access to Document

10.1097/INF.0000000000000972

Cite this

@article{de4371e94d1c4c77a2ec6072987a2335,

title = "Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients",

abstract = "This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35\%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second\% predicted remained unchanged during 12 months.",

keywords = "airway infection, cystic fibrosis, extended spectrum β-lactamase, producing Enterobacteriaceae",

author = "Huda Mussaffi and Shvalb, \{Naama Fisch\} and Haim Ben-Zvi and Gilat Livni and Meir Mei-Zahav and Dario Prais and Patrick Stafler and Guy Steuer and Hannah Blau",

note = "Publisher Copyright: {\textcopyright} 2015 Wolters Kluwer Health, Inc.",

year = "2016",

month = feb,

day = "1",

doi = "10.1097/INF.0000000000000972",

language = "אנגלית",

volume = "35",

pages = "216--219",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

AU - Mussaffi, Huda

AU - Shvalb, Naama Fisch

AU - Ben-Zvi, Haim

AU - Livni, Gilat

AU - Mei-Zahav, Meir

AU - Prais, Dario

AU - Stafler, Patrick

AU - Steuer, Guy

AU - Blau, Hannah

PY - 2016/2/1

Y1 - 2016/2/1

N2 - This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second% predicted remained unchanged during 12 months.

AB - This case series describes 18 cystic fibrosis (CF) patients of a 135-patient CF center cohort with extended spectrum β-lactamase-producing Enterobacteriaceae, from 2003 to 2012. Four had chronic infection. Prevalence increased annually from 0 to 6.35%. Risk factors compared with the 2010 CF center cohort included continuous inhaled antibiotics (P = 0.014) and courses of intravenous antibiotics during the year before first isolation (P = 0.009). Hospitalization rates were 1.05/year and 0.47/year preinfection and postinfection, respectively (P = 0.02). Slope of forced expiratory volume at 1 second% predicted remained unchanged during 12 months.

KW - airway infection

KW - cystic fibrosis

KW - extended spectrum β-lactamase

KW - producing Enterobacteriaceae

UR - https://www.scopus.com/pages/publications/84955369187

U2 - 10.1097/INF.0000000000000972

DO - 10.1097/INF.0000000000000972

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:84955369187

SN - 0891-3668

VL - 35

SP - 216

EP - 219

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 2

ER -

Clinical Impact of β-Lactamase-producing Enterobacteriaceae in Sputum of Cystic Fibrosis Patients

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this